BioMedNewsBreaks Archive - BioMedWire (BMW)

MondayOct 14, 2024 3:40 pm

BioMedNewsBreaks — Astiva Health Providing Standout Option During Medicare Open Enrollment Period

Astiva is a leading provider of personalized and comprehensive healthcare solutions to diverse communities. “Medicare open enrollment for 2024-2025 begins on Oct. 15, 2024, and closes on Dec. 7, 2024, as noted in a recent Medicare Advocates article… Astiva Health provides a standout option during this critical enrollment period, offering a health plan designed to meet the specialized needs of its members,” a recent article reads. “A key feature of Astiva’s plans is its unmatched rebates and grocery benefits. Members are eligible to receive the full Part B premium rebate of $174.70 monthly, helping to alleviate the financial burden of healthcare…

ThursdayOct 10, 2024 1:08 pm

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Management, Dr. Samuel Goldlust Participate in Virtual Investor KOL Connect Segment

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company announced Thursday morning that it participated in a Virtual Investor KOL Connect segment. Members of the company’s management team and Dr. Samuel Goldlust, who previously served as an investigator in the company’s global potentially pivotal study of Berubicin, joined the segment to provide a corporate update, discuss the unmet need in glioblastoma multiforme (“GBM”), and highlight the opportunity for the company. To access the segment, visit https://ibn.fm/V1eC1 To view the full…

WednesdayOct 09, 2024 1:35 pm

BioMedNewsBreaks — Oragenics, Inc. (NYSE American: OGEN) Reports on Lead Candidate Drug Development, ‘Urgency’ to Advance First-in-Class Concussion Treatment

Oragenics (NYSE American: OGEN), a biopharmaceutical company committed to developing novel therapies for neurological disorders, has released a corporate update. Highlights of shareholder report include an overview of key milestones reached this year as the company has developed its lead candidate, ONP-002, a first-in-class neurosteroid designed for the treatment of concussions. Those milestones include strengthening the company’s clinical leadership, preparing for a phase 2 clinical trial, successful cardiotoxicity testing and required genotoxicity studies and establishing a key partnership with Avance Clinical, a leading contract research organization (“CRO”). “Our mission is to address significant unmet medical needs by developing cutting-edge therapies,”…

TuesdayOct 08, 2024 12:30 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Featured in Fireside Chat at 2024 Healthcare Virtual Summit

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be participating in the upcoming 2024 Healthcare Virtual Summit. The summit, which is presented by Maxim Group LLC, is scheduled for Oct. 16, 2024. According to the announcement, CNS Pharmaceuticals CEO John Climaco will be part of a fireside chat, slated to begin at 4 p.m. ET during the one-day event. In addition to the fireside chat, the summit will include presentations, interactive discussions and topical industry panels with an array of biotechnology,…

MondayOct 07, 2024 2:34 pm

BioMedNewsBreaks — Roth Capital Partners with IBN as Official Media Sponsor of Annual Roth Healthcare Opportunities Conference

Roth Capital Partners (Roth MKM), a relationship-driven investment bank dedicated to serving growth companies and their investors, is partnering with IBN as an official media sponsor for this week’s third annual Roth Healthcare Opportunities Conference. The invitation-only, one-day conference is scheduled for Oct. 9, 2024, in New York City. According to the announcement, IBN will leverage its extensive corporate communications network to increase awareness of the conference, which is an exclusive platform that gathers together veteran investors with C-suite executives from public and private companies in the healthcare sector. “ROTH's upcoming conference is set to showcase some of the most…

MondayOct 07, 2024 10:55 am

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Announces ‘Significant’ Extension and Expansion of Exclusive Distribution Agreement with OPKO Health

NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, today announced that its original exclusive e-commerce distribution contract with OPKO Health Inc. (NASDAQ: OPK) has been extended for four years and expanded to include additional e-commerce platforms and digital and social media marketing across China. The original agreement allowed NextPlat to sell OPKO Health Europe’s nutraceutical and veterinary products on the Tmall Global e-commerce platform only. According to the announcement, the expanded contract also grants NextPlat the exclusive rights to sell and market OPKO products in Japan. “The significant extension and expansion of our agreement with OPKO is evidence of the…

ThursdayOct 03, 2024 2:30 pm

BioMedNewsBreaks — 180 Life Sciences Corp. (NASDAQ: ATNF) Provides Update on Strategic Corporate Initiatives

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has released an update on several key initiatives, including announcing the acquisition of an advanced Gaming Technology Platform, positive progress on its Legacy CBD formulation and a strengthened balance sheet. According to the update, the company is shifting its focus as it enters the global iGaming market through its acquisition of a comprehensive intellectual property package, consisting of a complete back-end technology solution for online casino operations. In addition, the company anticipates retaining its current portfolio of biotechnology intellectual property as it reports positive study results exhibiting faster absorption and improved…

ThursdayOct 03, 2024 2:18 pm

BioMedNewsBreaks — TC BioPharm Holdings PLC (NASDAQ: TCBP), Carnegie Mellon University Partner to Potentially Revolutionize Donor Selection, Matching Processes with AI

TC BioPharm (NASDAQ: TCBP), a clinical stage biotechnology company developing allogeneic gamma-delta T cell therapies for cancer and other indications, today announced its sponsored research agreement with Carnegie Mellon University. Under the agreement, TC BioPharm is partnering with Dr. Wei Wu, a faculty member in the Ray and Stephanie Lane Computational Biology Department within the university’s School of Computer Science, and her lab to explore the potential use of artificial intelligence (“AI”) to enhance the donor selection and matching processes. “Dr. Wu and her laboratory are helping us tackle another ‘big problem’ with this endeavor, which has the potential to revolutionize…

WednesdayOct 02, 2024 11:50 am

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Schedules Live Investor Webinar, Q&A Session

Nutriband (NASDAQ: NTRB), a pharmaceutical company with a special focus on transdermal technologies, will be part of an upcoming live webinar hosted by RedChip Companies. Scheduled for October 17, 2024, at 4:15 p.m. ET, the exclusive event will feature Gareth Sheridan, Founder and CEO, and Serguei Melnik, Founder and President. Sheridan and Melnik will share insight into Nutriband’s current operations and upcoming milestones as well as field questions from listeners and investors. To register for the free webinar, visit https://ibn.fm/FAbNx To view the full press release, visit https://ibn.fm/WYRB1 About Nutriband Inc. Nutriband is primarily engaged in the development of a…

WednesdayOct 02, 2024 9:30 am

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Closes on Direct Offering, Concurrent Private Placements Totaling $7.3M

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, and its wholly owned subsidiary, Clene Nanomedicine Inc., has closed on a registered direct offering and concurrent private placements. According to the announcement, the transactions consist of common stock and warrants and were with a healthcare-focused institutional investor and existing shareholders, including insiders. Gross proceeds of the offerings and placements totaled an estimated $7.3 million with the potential for additional capital through the future exercise of warrants. Clene also announced the amendment of its existing debt facility with Avenue Venture…

News and publishing service for medical and biotechnology related companies

Contact us: 415.949.5050

BioMedNewsBreaks

BioMedNewsBreaks — Astiva Health Providing Standout Option During Medicare Open Enrollment Period

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Management, Dr. Samuel Goldlust Participate in Virtual Investor KOL Connect Segment

BioMedNewsBreaks — Oragenics, Inc. (NYSE American: OGEN) Reports on Lead Candidate Drug Development, ‘Urgency’ to Advance First-in-Class Concussion Treatment

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Featured in Fireside Chat at 2024 Healthcare Virtual Summit

BioMedNewsBreaks — Roth Capital Partners with IBN as Official Media Sponsor of Annual Roth Healthcare Opportunities Conference

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Announces ‘Significant’ Extension and Expansion of Exclusive Distribution Agreement with OPKO Health

BioMedNewsBreaks — 180 Life Sciences Corp. (NASDAQ: ATNF) Provides Update on Strategic Corporate Initiatives

BioMedNewsBreaks — TC BioPharm Holdings PLC (NASDAQ: TCBP), Carnegie Mellon University Partner to Potentially Revolutionize Donor Selection, Matching Processes with AI

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Schedules Live Investor Webinar, Q&A Session

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Closes on Direct Offering, Concurrent Private Placements Totaling $7.3M

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search